Neuren Pharmaceuticals Limited

Press Releases

2006-December-19	Neuren Engages Burrill & Company to Progress Out-licensing Opportunities (in PDF)
2006-November-3	Neuren Successfully Raises $1.6 Million Through Share Purchase Plan (in PDF)
2006-October-20	Neuren Research Shows Cancer Regression in Preclinical Model (in PDF)
2006-October-16	Neuren's Third Lead Drug Candidate, NNZ-2591, Proves Effective at Reversing Memory Loss (in PDF)
2006-September-27	Positive Preclinical Results Show Fat Reduction Capability for Neuren's Compound NNZ-3006 (in PDF)
2006-September-4	US Army to Conduct Phase 2 Trial of Glypromate® to Reduce Brain Injury from Cardiac Arrest (in PDF)
2006-August-22	Favourable Phase 2a Pharmacokinetic and Safety Data for Glypromate® Confirmed (in PDF)
2006-August-14	Neuren Presents Phase 2 Clinical Trial Strategy for NNZ-2566 (in PDF)
2006-August-2	Neuren Selects New Compound Targeted for the Oral Treatment of Parkinson's and Related Neurological Diseases (in PDF)
2006-July-18	Neuren Appoints Chief Operating Officer (in PDF)
2006-July-11	NRP Collaboration: Research on Nerve Protection Compounds Published in Science Journal (in PDF)
2006-May-29	US Army Presents New Neuren Research Results at International Neuroscience Meeting (in PDF)
2006-May-11	Neuren Granted US Patent for NNZ-2566 (in PDF)
2006-April-26	Neuren and US Army Continued Success in Traumatic Brain Injury Program and now File Joint Patent (in PDF)
2006-April-12	Neuren Reports Successful Phase 2 Results (in PDF)
2006-March-22	Preclinical Results for Oral Administration of NNZ-2566 Opens up Significant New Market Opportunities (in PDF)
2006-March-6	Neuren's Second Lead Compound to Commence Phase 1 Trial (in PDF)
2006-February-16	Neuren and Metabolic Report Promising Animal Efficacy Data in Collaborative Project (in PDF)
2007	2007 Press Releases